Form D · Biotechnology
Altheus Therapeutics Inc
Oklahoma City, OK · CIK 0001414163
Offering snapshot reported Jan 23, 2014 · SEC filing
- Reported sold
- $8.09M Offering amount: $8.09M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $967 Reported outside-investor minimum
- First sale
- Feb 24, 2012 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$6,850,850 → $8,085,705
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 23, 2014 | Amendment | $8,085,705 | $1,234,855vs Oct 25, 2013 | 21 | SEC filing |
| Oct 25, 2013 | Amendment | $6,850,850 | $999,999vs Jan 4, 2013 | 21 | SEC filing |
| Jan 4, 2013 | Amendment | $5,850,851 | $525,000vs Mar 9, 2012 | 20 | SEC filing |
| Mar 9, 2012 | Initial | $5,325,851 | No comparison | 12 | SEC filing |
| Dec 8, 2011 | Amendment | $1,970,243 | $1,470,181vs May 11, 2009 | 11 | SEC filing |
| Jul 13, 2011 | Amendment | $1,815,753 | $1,315,691vs May 11, 2009 | 11 | SEC filing |
| Jun 4, 2010 | Amendment | $1,713,296 | $520,876vs Oct 5, 2009 | 10 | SEC filing |
| Oct 5, 2009 | Amendment | $1,192,420 | $692,358vs May 11, 2009 | 9 | SEC filing |
| May 11, 2009 | Initial | $500,062 | No comparison | Not reported | SEC filing |
| Oct 2, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-174656
The total amount was sold in multiple tranches. There was an additional $109,736 of the securities offered to current shareholders under a right of first refusal which was not exercised, and such amount will not be sold. The final tranche closed 1-6-14.
Source: Form D, filed Jan 23, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alpha Bio Partners, Inc. | Promoter |
| Douglas A. Branch | Director |
| Brian L. Clevinger | Director |
| Richard F. Harty, Md | Executive |
| Alpha Bio Partners, Inc. | Promoter |
| William Paiva | Director |
| Dayton T. Reardan | Executive |
| Dennis Schafer | Director, Executive |
| James Schoeneck | Director |
| Thomas L. Shoaf | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
755 Research Parkway Suite 435
Oklahoma City, OK, 73104
Oklahoma City, OK, 73104